AMENDMENTS TO THE CLAIMS:

Please amend claims 1-42 as follows:

1. (Original) A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound (s) (NO-donating NSAID (s)) absorbed into porous particles.

2. (Original) The solid drug delivery composition according to claim 1 wherein one or more NO- donating NSAID(s) in oily form is absorbed into porous particles.

3. (Original) The solid drug delivery composition according to claim 1 wherein one or more NO- donating NSAID(s) in melted form is absorbed into porous particles.

4. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 3~~ wherein the porous particles are selected from the group consisting of dibasic calcium phosphate, anhydrous, microcrystalline cellulose and pregelatinised starch or a mixture thereof.

5. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 4~~ wherein the porous particles are spherical with a particle size between 50 and 500 um.

6. (Original) The solid drug delivery composition according to claim 5 wherein the particle size of the spherical porous particles is between 100 and 150 um.

7. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 4~~ wherein the pore size of the porous particles is between 10 and 1000 Å.

8. (Original) The solid drug delivery composition according to claim 7 wherein the pore size of the porous particles is between 20 and 750 Å.

9. (Original) The solid drug delivery composition according to claim 8 wherein the pore size of the porous particles is between 50 and 500 Å.

10. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 9~~ wherein one or more NO-donating NSAID(s) is absorbed together with one or more surfactant (s) into the porous particles.

11. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 9~~ comprising a combinations of
a) porous particles comprising an NO-donating NSAID and one or more surfactant(s) and
b) porous particles comprising an NO-donating NSAID without surfactant.

12. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 10 ~~or 11~~ wherein the NO-donating NSAID(s) are the same.

13. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 10 ~~to 12~~ wherein the surfactant (s) is non-ionic.

14. (Original) The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a block co-polymer.

15. (Original) The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a poloxamer.

16. (Original) The solid drug delivery composition according to claim 13 wherein the surfactant(s) is a polyoxyethylene polyoxybutylene block copolymer.

17. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 10 ~~to 16~~ wherein the ratio NO-donating NSAID(s): surfactant(s) is within the range from 1:0.1 to 1:10(w/w).

18. (Original) The solid drug delivery composition according to claim I7 wherein the ratio NO-donating NSAID(s): surfactant(s) is within the range from 1:0.3 to 1:3(w/w).

19. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 18~~ wherein the NO-donating NSAID is an NO-donating naproxen.

20. (Original) The solid drug delivery composition according to claim 19 wherein the NO-donating naproxen is 4-(nitrooxy)butyl-(S)-2- (9-methoxy-2-naphtyl)-propanoate.

21. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 18~~ wherein the NO-donating NSAID is an NO-donating diclofenac.

22. (Original) The solid drug delivery composition according to claim 21 wherein the NO-donating diclofenac is 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid 4-(nitrooxy)-butyl ester.

23. (Original) The solid drug delivery composition according to claim 21 wherein the NO-donating diclofenac is 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2, 6-dichlorophenyl)amino] phenyl} acetate.

24. (Currently Amended) The solid drug delivery-composition according to ~~any one of~~ claims 1 ~~to 18~~ wherein the NO-donating NSAID is an NO-donating ketoprofen.

25. (Original) The solid drug delivery composition according to claim 24 wherein the NO-donating ketoprofen is 2-(3-benzoyl-phenyl)-propionic acid 3-nitrooxy-propyl ester or 2-(3-benzoyl-phenyl)-propionic acid 4-nitrooxymethyl-benzyl ester.

26. (Currently Amended) The solid drug delivery composition according to ~~any one of~~ claims 1 ~~to 25~~ wherein the porous particles comprising an NO-donating NSAID, optionally mixed with one or more surfactant(s), are mixed together with enteric coated pellets comprising a H+,K+-ATPase inhibitor.

27. (Original) The solid drug delivery composition according to claim 26 wherein the porous particles comprising an NO-donating naproxen, an NO-donating diclofenac, an NO-donating ketoprofen or an NO-donating ketorolac, optionally mixed with one or more surfactant(s), are mixed together with enteric coated pellets comprising omeprazole, esomeprazole, lansoprazole, pantoprazole or rabeprazole, leminoprazole or a pharmaceutical acceptable salt thereof.

28. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to ~~any one of~~ claims ~~1 to 25~~ comprising mixing the NO-donating NSAID(s), optionally in oily or melted form, with porous particles.

29. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to ~~any one of~~ claims ~~1 to 25~~ comprising:
a) dissolving the NO-donating NSAID(s) in one or more alcohol(s),
b) adding the porous particles during stirring,
c) evaporating the added alcohol(s),
d) recovering the porous particles comprising the NO-donating NSAID(s),
with a) and b) in optional order.

30. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to ~~any one of~~ claims ~~1 to 25~~ comprising:
a) melting the NO-donating NSAID(s),
b) adding the porous particles,
c) stirring the obtained mixture,
d) recovering the porous particles comprising the NO-donating NSAID(s),
with a) and b) in optional order.

31. (Currently Amended) Process for producing porous particles comprising one or more NO-donating NSAID(s) and one or more surfactant(s) according to ~~any one of~~ claims ~~1 to 25~~ comprising:
a) mixing the NO-donating NSAID(s) and the surfactant(s),

b) adding the porous particles,
c) stirring the obtained mixture,
d) recovering the porous particles comprising the NO-donating NSAID(s) and the surfactant(s),
with a) and b) in optional order.

32. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) and one or more surfactant(s) according to ~~any one of~~ claims ~~1 to 25~~ comprising :
a) melting NO-donating NSAID(s) and the surfactant(s),
b) adding the porous particles,
c) stirring the obtained mixture,
d) recovering the porous particles comprising NO-donating NSAID(s) and the surfactant (s),
with a) and b) in optional order.

33. (Currently Amended) Process for producing the porous particles comprising one or more NO-donating NSAID(s) according to ~~any one of~~ claims 1 ~~to 25~~ comprising:
a) mixing the NO-donating NSAID(s) and the porous excipient,
b) adding water, stepwise, continuously, in one portion,
c) extruding the obtained mixture into particles,
d) spheronising the obtained particles,
e) drying the obtained mixture,
f) recovering the porous particles comprising the NO-donating NSAID(s).

34. (Original) The process according to claim 33 wherein the NO-donating NSAID(s) in step a) is pre-heated.

35. (Currently Amended) The process according to ~~any one of~~ claims 28 ~~to 34~~ wherein the NO-donating NSAID(s) are the same.

36. (Currently Amended) ~~The~~A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound (s) (NO-donating NSAID (s)) absorbed into porous particles ~~the porous particles according to any one of claims 1 to 25~~ wherein the porous particles have been produced according to ~~any one of~~ claims 28 ~~to 35~~, are mixed with pharmaceutically acceptable excipients and compressed into a tablet.

37. (Currently Amended) ~~The~~A solid drug delivery composition comprising one or more NO-donating Non Steroidal Antiinflammatory Compound (s) (NO-donating NSAID (s)) absorbed into porous particles ~~the porous particles according to any one of claims 1 to25~~ wherein the porous particles have been produced according to ~~any one of~~ claims ~~28 to 35~~, are filled into a capsule.

38. (Currently Amended) The solid drug delivery composition according to claims 36 ~~and 37~~ wherein the capsules or tablets are coated.

39. (Currently Amended) Use of the solid drug delivery composition according to ~~any one of the~~ claims ~~1 to 27~~ for the manufacture of a medicament for treating pain.

40. (Currently Amended) Use of the solid drug delivery composition according ~~according~~ to ~~any one of the~~ claims 1 ~~to 27~~ for the manufacture of a medicament for treating inflammation.

41. (Currently Amended) A method for the treatment of pain comprising oral administration to a patient suffering therefrom a solid compound delivery composition according to ~~any one of~~ claims ~~1 to 27~~.

42. (Currently Amended) A method for the treatment of inflammation comprising oral administration to a patient suffering therefrom a solid compound delivery composition according to ~~any one of~~ claims 1 ~~to 27~~.